-
At the end of the year, financing in the pharmaceutical field was frequent, and the pharmaceutical company completed a B+ round of financing of more than 100 million yuan
Time of Update: 2022-12-30
According to the data, Huaxian Pharmaceutical is a one-stop CRO & CDMO service platform enterprise, and the company relies on the core technologies in chiral synthesis, biological enzyme catalysis and continuous flow microchannels to develop high-difficulty characteristic APIs and intermediates in the fields of anti-tumor, antiviral and anti-respiratory diseases.
-
In December, a large number of pharmaceutical companies were fined for announcing that the fine reached hundreds of millions of yuan
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];With the implementation and advancement of the new version of the Drug Administration Law and the tightening of the supervision of the pharmaceutical industry, a large number of pharmaceutical companies' illegal sales of inferior drugs and illegal operations are being exposed one after another, which continues to wake up the industry.
-
"Innovation" has become the main theme of the development of the domestic medical device industry!
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];In recent years, under the promotion of multiple advantages such as encouraging innovative medical devices, marginal easing of centralized procurement policies, and supporting equipment renewal with financial discounted loans, the development of the domestic medical device industry is accelerating.
-
How innovative drugs extend the golden years
Time of Update: 2022-12-30
Follow-up commercialization is difficult Analysis of the seven years of innovative drug development practice of Chinese pharmaceutical companies, especially innovative pharmaceutical companies, from 2016 to 2022 shows that commercialization, including internationalization, is still being explored, mainly reflected in insufficient preparation, lagging commercialization starting point and insufficient experience in the marketization of original innovative drugs.
-
China has adjusted and optimized nucleic acid testing in many places and taken multiple measures to meet the needs of medical treatment and medicine
Time of Update: 2022-12-30
Medical institutions no longer check nucleic acid results At a press conference on the State Council's joint prevention and control mechanism earlier this month, Guo Yanhong, director of the Department of Medical Emergency Response of the National Health Commission, stressed that the treatment of patients must not be premised on whether they have nucleic acid test results.
-
Recently, the sales of some drugs have soared, and pharmaceutical glass companies have attracted the attention of investors
Time of Update: 2022-12-30
Recently, with the liberalization of policies and the issuance of home health guidelines by the National Health Commission, the sales of vaccines, traditional Chinese medicines, and analgesic and ant
-
In less than 1 month, the stock price of Xinhua Pharmaceutical has risen by more than 2 times, what is the confidence?
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];Recently, Xinhua Pharmaceutical has won six consecutive boards, and the stock price has risen more than twice since November, from 17.
js?cdnversion='+~(-new Date()/36e5)];Recently, Xinhua Pharmaceutical has won six consecutive boards, and the stock price has risen more than twice since November, from 17.
-
CDE: Notice on the requirements for electronic declaration of drug registration applications released!
Time of Update: 2022-12-30
Preparation of electronic declaration materialsThe applicant shall prepare electronic declaration materials (including letters of commitment) in accordance with the current regulations, technical requirements for electronic CD-ROMs of application materials, and electronic file structure of drug registration applications, and submit the CD-ROMs to the Drug Review Center to submit an application for drug registration.
-
2022 annual inventory: 70 billion US dollars, a big year for global mergers and acquisitions! Novartis and GSK "interact" frequently, Pfizer 5 times to the bottom of the attempt...
Time of Update: 2022-12-30
The total amount of mergers and acquisitions exceeded $70 billion Pfizer rode the dust The capital winter also accelerates the M&A process between pharmaceutical companies.
The total amount of mergers and acquisitions exceeded $70 billion Pfizer rode the dust The capital winter also accelerates the M&A process between pharmaceutical companies.
-
The purchase of 35 Chinese medicine pieces such as American ginseng, bezoar and goji berry leaves was suspended
Time of Update: 2022-12-30
The combing found that the Chinese medicine pieces suspended this time included fried locust rice (flower), yellow lip gum, pearls, wolfberry leaves, lamp charcoal, forest ginseng, red ginseng whiskers, red ginseng reed, American ginseng, Inner Mongolian comfrey, cordyceps, deer antler blood tablets, deer antler powder tablets, deer tendon, sand fried leopard bones, sand fried monkey bones, antelope horn tip powder, etc.
-
Amgen, Johnson & Johnson and Sanofi may bid on the same stage! BI, AstraZeneca, Biogen, Hehuang, Hua Ling and other pharmaceutical companies personnel changes!
Time of Update: 2022-12-30
1. The heads of the four major sectors of AstraZeneca China "arrived" On November 23, Guan Dongmei officially became the new vice president and head of the cardiovascular, renal and metabolic business unit of AstraZeneca China, and reported directly to Lai Minglong, general manager of AstraZeneca China, as a member of the China management team.
-
Under the tide of cooperation between pharmaceutical companies, the development of new drugs is accelerating
Time of Update: 2022-12-30
GenFleet partners with Merck of Germany On December 19, GenFleet announced that it has entered into a European multi-center clinical research and drug supply collaboration agreement with Merck KGaA to conduct a Phase 1b/2 clinical study of GenFleet's combination therapy with KRAS G12C inhibitor GFH925 and Merck's anti-EGFR antibody cetuximab injection to evaluate the effectiveness of this combination therapy in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC).
-
10 domestic new crown epidemic seedlings data revealed, who can "kerong"?
Time of Update: 2022-12-30
According to the company's Phase 3 clinical data published in The Lancet in January 2022, Kwesha targeted the original strain:After 14 days of vaccination, the overall effective rate was 63.
-
mRNA vaccine second half: Moderna has switched to cancer treatment, clinically reducing the risk of recurrence and death by 44%.
Time of Update: 2022-12-30
On October 12, 2022, Merck and Moderna signed a $250 million partnership agreement for the joint development and commercialization of the Personalized Cancer Vaccine (PCV) mRNA-4157/V940 。 On December 13, Moderna's official website announced that the combination of personalized cancer vaccine mRNA-4157/V940 and PD-1 inhibitor Keytruda showed that compared with Keytruda monotherapy, it can significantly reduce the risk of recurrence or death in stage III and IV melanoma patients after complete tumor resection by 44%!
-
Jiangsu: Notice on further strengthening the work of ensuring the supply and price of medical supplies
Time of Update: 2022-12-30
On December 17, the Jiangsu Provincial Market Supervision Bureau and the Food and Drug Administration jointly issued the Notice on Further Strengthening the Work of Ensuring the Supply and Stabilizin
-
The outline of the preparation of the Chinese Pharmacopoeia (2025 edition) has been released!
Time of Update: 2022-12-30
From: National Pharmacopoeia Editor: Crystal On December 19, the Pharmacopoeia Commission released the outline of the Chinese Pharmacopoeia (2025 edition). The Outline points out that by 2025, the pr
-
Notice on the issuance of measures for the graded management of surgical procedures in medical institutions
Time of Update: 2022-12-30
Health commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps: In order to strengthen the hierarchic
-
Another group of domestic and foreign pharmaceutical executives proposed to leave at the end of the year
Time of Update: 2022-12-30
On December 13, Chengdu Pilot announced that Mr. Wan Jinqiao, a senior manager and core technical personnel of the company, recently submitted a resignation application to the company due to personal reasons, and will no longer hold any position in the company after his resignation.
-
Since December, many pharmaceutical companies have encountered setbacks in drug research and development
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];On December 19, AstraZeneca announced that the drug Imfinzi, as a monotherapy for patients with advanced non-small cell lung cancer, failed to achieve its primary goal of improving overall survival compared to platinum-based chemotherapy.
-
Drug supply war under the epidemic: pharmaceutical factories do not stop production
Time of Update: 2022-12-30
From: Dandelion (ouryao. com) Finishing: Green to blue Recently, there has been a shortage of antipyretic and analgesic drugs such as ibuprofen in many places, in order to ensure the market supply of
